E. Klumper

959 total citations
19 papers, 590 citations indexed

About

E. Klumper is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, E. Klumper has authored 19 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Public Health, Environmental and Occupational Health, 7 papers in Molecular Biology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in E. Klumper's work include Acute Lymphoblastic Leukemia research (11 papers), Cancer therapeutics and mechanisms (6 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). E. Klumper is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), Cancer therapeutics and mechanisms (6 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). E. Klumper collaborates with scholars based in Netherlands, United Kingdom and Spain. E. Klumper's co-authors include A. Veerman, Gertjan J.L. Kaspers, Rob Pieters, K. Hählen, Rob Pieters, F. C. de Waal, R. Hartmann, G. Henze, ER van Wering and R. Pieters and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

E. Klumper

18 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Klumper Netherlands 11 353 238 228 191 140 19 590
C. H. Van Zantwijk Netherlands 13 475 1.3× 257 1.1× 258 1.1× 116 0.6× 194 1.4× 19 672
RM Stone United States 9 469 1.3× 570 2.4× 282 1.2× 215 1.1× 158 1.1× 13 940
Shirley Kow Yin Kham Singapore 15 391 1.1× 205 0.9× 194 0.9× 84 0.4× 247 1.8× 33 669
M. M. A. Rottier Netherlands 7 178 0.5× 103 0.4× 176 0.8× 150 0.8× 73 0.5× 9 394
P R Taylor United Kingdom 11 177 0.5× 323 1.4× 158 0.7× 137 0.7× 38 0.3× 20 517
Ángela Gutiérrez-Camino Spain 16 285 0.8× 124 0.5× 338 1.5× 162 0.8× 187 1.3× 37 667
Anna Grazia Recchia Italy 16 154 0.4× 302 1.3× 265 1.2× 166 0.9× 66 0.5× 38 653
April Sorrell United States 9 201 0.6× 314 1.3× 114 0.5× 90 0.5× 71 0.5× 18 498
Joanna Trelińska Poland 12 166 0.5× 70 0.3× 172 0.8× 199 1.0× 138 1.0× 37 501
Aurore Touzart France 12 199 0.6× 181 0.8× 143 0.6× 81 0.4× 66 0.5× 24 424

Countries citing papers authored by E. Klumper

Since Specialization
Citations

This map shows the geographic impact of E. Klumper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Klumper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Klumper more than expected).

Fields of papers citing papers by E. Klumper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Klumper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Klumper. The network helps show where E. Klumper may publish in the future.

Co-authorship network of co-authors of E. Klumper

This figure shows the co-authorship network connecting the top 25 collaborators of E. Klumper. A scholar is included among the top collaborators of E. Klumper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Klumper. E. Klumper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chowdhury, Simon, Alison Birtle, Anders Bjartell, et al.. (2017). Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. Journal of Clinical Oncology. 35(6_suppl). 212–212. 3 indexed citations
2.
Chowdhury, Simon, Alison Birtle, Anders Bjartell, et al.. (2017). Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.. Journal of Clinical Oncology. 35(15_suppl). 5028–5028. 3 indexed citations
3.
Azaro, Analía, Elizabeth Ruth Plummer, Ander Urruticoechea, et al.. (2017). Final report of a phase I study of 2-hydroxyoleic acid (2OHOA) a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including recurrent high grade gliomas (rHGG).. Journal of Clinical Oncology. 35(15_suppl). 2554–2554. 8 indexed citations
4.
5.
Chowdhury, Susmita, Anders Bjartell, Laura Galli, et al.. (2015). 2548 The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC). European Journal of Cancer. 51. S492–S492. 1 indexed citations
6.
Hartmann, R., Christoph Bührer, B. R. Winterhalter, et al.. (1997). Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia. European Journal Of Haematology. 58(5). 326–332. 5 indexed citations
7.
Pieters, Rob, E. Klumper, Gertjan J.L. Kaspers, & A. Veerman. (1997). Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology. 25(1). 11–26. 46 indexed citations
8.
Klumper, E., et al.. (1996). IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA. British Journal of Haematology. 93(4). 903–910. 42 indexed citations
9.
Klumper, E., R. Pieters, Monique L. den Boer, et al.. (1995). In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. British Journal of Cancer. 71(6). 1188–1193. 17 indexed citations
10.
Klumper, E., et al.. (1995). In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.. PubMed. 9(11). 1864–9. 39 indexed citations
11.
Schuurhuis, G.J., H J Broxterman, GJ Ossenkoppele, et al.. (1995). Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.. PubMed. 1(1). 81–93. 72 indexed citations
12.
Klumper, E., et al.. (1995). Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.. PubMed. 9(10). 1653–60. 24 indexed citations
13.
Klumper, E., Rob Pieters, A. Veerman, et al.. (1995). In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 86(10). 3861–3868. 167 indexed citations
14.
Kaspers, Gertjan J.L., Rob Pieters, E. Klumper, F. C. de Waal, & A. Veerman. (1994). Glucocorticoid Resistance in Childhood Leukemia. Leukemia & lymphoma. 13(3-4). 187–201. 81 indexed citations
15.
Kaspers, Gertjan J.L., G Kardos, Raymond Pieters, et al.. (1994). Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.. PubMed. 8(7). 1224–9. 39 indexed citations
16.
Pieters, Rob, Gertjan J.L. Kaspers, E. Klumper, & A. Veerman. (1994). Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art. Medical and Pediatric Oncology. 22(5). 299–308. 23 indexed citations
17.
Pieters, Rob, Gertjan J.L. Kaspers, E. Klumper, et al.. (1994). [Clinical relevance of resistance against cytostatic agents in children with leukemia].. PubMed. 138(14). 706–12.
18.
Kaspers, Gertjan J.L., et al.. (1994). In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.. PubMed. 8(1). 24–9. 18 indexed citations
19.
Kaspers, Gertjan J.L., R. Pieters, E. Klumper, F. C. de Waal, & A. Veerman. (1993). [The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments].. PubMed. 61(1). 1–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. H. Van Zantwijk Breakdown of academic impact, for papers by RM Stone Breakdown of academic impact, for papers by Shirley Kow Yin Kham Breakdown of academic impact, for papers by M. M. A. Rottier Breakdown of academic impact, for papers by P R Taylor Breakdown of academic impact, for papers by Ángela Gutiérrez-Camino Breakdown of academic impact, for papers by Anna Grazia Recchia Breakdown of academic impact, for papers by April Sorrell Breakdown of academic impact, for papers by Joanna Trelińska Breakdown of academic impact, for papers by Aurore Touzart
Rankless by CCL
2026